Osteoporosis and Risk of Hearing Loss: Protective Effects of Zoledronic Acid and Denosumab in a Nationwide Cohort.

For Objective 1, adults aged 65 years and older with osteoporosis or fragility fractures (n = 331,867) and matched controls (n = 331,867); for Objective 2, patients with osteoporosis or fragility fractures treated with zoledronic acid (n = 21,811), treated with denosumab (n = 21,811), or without treatment (n = 21,811).